Trade

with

Durata Therapeutics Inc
(NASDAQ: DRTX)
AdChoices
23.98
-0.04
-0.17%
After Hours :
23.98
0.00
0.00%

Open

23.95

Previous Close

24.02

Volume (Avg)

364.78k (602.27k)

Day's Range

23.87-24.05

52Wk Range

9.15-24.33

Market Cap.

642.12M

Dividend Rate ( Yield )

-

Beta

3.96

Shares Outstanding

26.78M

P/E Ratio (EPS)

-

AdChoices
Ownership

Institutional Ownership

93.77%

Top 10 Institutions

76.12%

Mutual Fund Ownership

18.01%

Float

58.33%

5% / Insider Ownership

0.62%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • Oppenheimer Global Opportunities

  •  

    1,000,000

  • 0.00

  • 3.73

  • Fidelity® Select Biotechnology Portfolio

  •  

    720,291

  • 0.00

  • 2.69

  • Vanguard VIF Small Comp Gr

  •  

    351,900

  • 38.94

  • 1.31

  • iShares Russell 2000 (AU)

  •  

    233,494

  • -1.45

  • 1.65

  • Vanguard US Discoveries Fund

  •  

    203,899

  • -2.25

  • 0.76

  • Vanguard Total Stock Mkt Idx

  •  

    201,930

  • 0.00

  • 0.75

  • Hartford Small Cap Growth HLS Fund

  •  

    177,687

  • 0.00

  • 0.66

  • Hartford SmallCap Growth Fund

  •  

    171,580

  • 12.93

  • 0.64

  • Northwestern Mutual Ser Sm Cp Gr Stk

  •  

    138,790

  • 0.00

  • 0.52

  • Fidelity Advisor® Biotechnology Fund

  •  

    129,737

  • 0.00

  • 0.48

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Domain Associates, LLC

  •  

    3,034,688

  • 0.00%

  • 11.39

  • New Leaf Ventures II LP

  •  

    3,028,439

  • 0.00%

  • 11.37

  • Aisling Capital Partners III LLC

  •  

    2,280,175

  • -24.75%

  • 8.56

  • Aisling Capital LLC

  •  

    2,030,175

  • -33.00%

  • 7.58

  • Wellington Management Company, LLP

  •  

    1,942,397

  • +3.14%

  • 7.25

  • Orbimed Advisors, LLC

  •  

    1,785,714

  • 0.00%

  • 6.67

  • Sofinnova Management VII, L.L.C.

  •  

    1,777,856

  • -21.73%

  • 6.67

  • Quaker BioVentures Capital II, LLC

  •  

    1,533,333

  • +15.00%

  • 5.76

Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

Distressed

Style

Small Growth

Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Key People

Mr. Paul R. Edick

CEO/Director/President

Mr. Corey N. Fishman

CFO/Chief Accounting Officer/COO

Wendy L. Yarno

Director

Nicole Vitullo

Director

Mr. Brenton K. Ahrens

Director

Incorporated

2009

Employees

-

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: